GlassScriptPhysician profile
Tailun Zhao
NPI 1952659203
$3,580.10
in general payments reported to CMS, 2019-2025
22 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.85 · 2020: $213 · 2021: $344 · 2022: $626 · 2023: $416 · 2024: $650 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $618.31 | 2024-2025 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $569.82 | 2020-2023 | Eylea, Eylea Hd |
| Bausch & Lomb Americas INC. | $569.11 | 2022-2025 | Envista Envy Iol, Stellaris, Miebo |
| Alcon Vision LLC | $388.42 | 2021-2025 | Tryptyr, Rocklatan, Eysuvis |
| Novartis Pharmaceuticals Corporation | $216.34 | 2019-2023 | |
| Glaukos Corporation | $200.53 | 2024 | Idose |
| Abbvie INC. | $189.56 | 2022-2025 | Ozurdex |
| Sun Pharmaceutical Industries INC. | $184.06 | 2020-2024 | Cequa |
| Genentech USA, INC. | $130.53 | 2022-2023 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $110.37 | 2024-2025 | Xdemvy |
| Astellas Pharma US INC | $90.64 | 2023-2025 | Izervay |
| Biogen, INC. | $82.49 | 2022-2024 | Byooviz |
| Aerie Pharmaceuticals, INC. | $35.89 | 2021 | |
| Harrow Eye, LLC | $32.63 | 2025 | Vevye |
| Coherus Oncology, INC. | $31.19 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $27.38 | 2023 | Vabysmo |
| Ani Pharmaceuticals, INC. | $20.00 | 2025 | Purified Cortrophin Gel |
| Kala Pharmaceuticals, INC. | $18.72 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.65 | 2021 | |
| Apellis Pharmaceuticals, INC. | $18.50 | 2023 | Syfovre |
| Horizon Therapeutics Plc | $14.41 | 2022 | |
| Oyster Point Pharma, INC. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tailun Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.